Sanofi’s Tzield approved amid review dispute as Bicillin shortage hampers syphilis treatment

An Arizona woman pregnant with syphilis could not receive timely treatment because of a worsening shortage of Bicillin, the injectable penicillin made by Pfizer. The shortage has raised concerns about access to essential antibiotics for vulnerable patients.

The FDA completed its review of Sanofi’s diabetes medication Tzield and granted approval, despite a notably contentious review process. The decision adds a new option for diabetes management to the market.

Separately, the Trump administration has suggested closing a Medicare negotiation loophole, a move that could affect drug pricing discussions. The article also references Lilly’s recent acquisition of Ajax, though details are not provided.